Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 16/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1730858 | 0.93 | F2R (0.43) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1729006 | 0.91 | KDM4E (0.46) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1729353 | 0.90 | KDM4E (0.46) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1731586 | 0.88 | KDM4E (0.45) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1731747 | 0.88 | KDM4E (0.43) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1730571 | 0.87 | F2R (0.46) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5490666 | 0.87 | KDM4E (0.48) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL1729080 | 0.87 | KDM4E (0.62) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1730145 | 0.86 | KDM4E (0.39) | F2RKDM4EMAPTRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL5484033 | 0.86 | KDM4E (0.39) | F2RKDM4EMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | claimed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | claimed |
| EP-3133075-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-30 | — | — | EP | claimed |
| EP-3336090-B1 | IRAK4 INHIBITOR AND USE THEREOF | BEIJING HANMI PHARMACEUTICAL CO LTD (CN) | 2020-07-22 | — | — | EP | claimed |
| EP-3050883-B1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-04-22 | — | — | EP | claimed |
| EP-2982666-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | claimed |
| EP-3239142-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-07-03 | — | — | EP | claimed |
| EP-2540728-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-10 | — | — | EP | claimed |
| EP-2750678-B1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC (US) | 2017-03-22 | — | — | EP | claimed |
| EP-2196459-B1 | 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-02 | — | — | EP | claimed |
| EP-1601669-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORP (US) | 2008-12-24 | — | — | EP | claimed |
| EP-1791825-B1 | BENZOYL-SUBSTITUTED SERINE AMIDES | BASF SE (DE) | 2008-09-17 | — | — | EP | claimed |
| EP-1601668-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORP (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1434485-B1 | NICOTINIC ACID-HETEROCYCLYL-AMIDES AND ANALOGOUS PYRIMIDINE DERIVATIVES FOR USE AS PESTICIDES | MERIAL LTD (US) | 2007-05-16 | — | — | EP | claimed |
| EP-1406609-B1 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1204675-B1 | STREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME | AVENTIS PHARMA SA (FR) | 2003-05-21 | — | — | EP | claimed |
| EP-1204675-A1 | STREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME | Aventis Pharma S.A. (FR) | 2002-05-15 | — | — | EP | claimed |
| WO-2001010895-A1 | STREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME | AVENTIS PHARMA S.A. (FR) | 2001-02-15 | — | — | WO | claimed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | claimed |
| EP-0074316-B1 | A PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 7-AMINOCEPHALOSPORANIC ACIDS | GEMA S.A. (ES) | 1986-12-30 | — | — | EP | claimed |